| Literature DB >> 18203009 |
Morie Gertz1, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, Nelson Leung, Mark Litzow.
Abstract
The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06 microg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06 microg/L had a day-100 all-cause mortality rate of 7% (P < 0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06 microg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18203009 DOI: 10.1080/10428190701684518
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022